GLAXOSMITHKLINE PHARMA LT (GLAXO) financials

GLAXOSMITHKLINE PHARMA LT (GLAXO) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Market Cap: ₹41,748Cr.
Current Price: ₹2,464
Stock P/E: 39.4
ROE: 43.3%
ROCE: 61.3%
Book Value: ₹132
Dividend Yield: 2.31%
52W High / Low: ₹3,121/2,088

In Jun 2026, GLAXOSMITHKLINE PHARMA LT (GLAXO) reported sales ₹924 Cr and net profit ₹253 Cr.

Annual TTM: sales ₹3,910 Cr, net profit ₹1,060 Cr.

Shareholding: Promoters 75.00% (Sep 2026), FIIs 4.75% (Sep 2026), DIIs 8.47% (Sep 2026), Government 0.00% (Sep 2026), Public 11.77% (Sep 2026).

GLAXO quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,000	946	966	805	974	1,023	989	924
Expenses	681	656	635	554	639	655	642	631
Operating Profit	319	290	331	251	335	368	347	293
OPM %	32%	31%	34%	31%	34%	36%	35%	32%
Other Income	37	35	39	44	34	32	36	62
Interest	0	0	1	0	1	1	1	1
Depreciation	17	19	15	16	17	20	13	16
Profit before tax	339	306	355	279	351	378	369	338
Tax %	27%	25%	27%	27%	27%	27%	26%	25%
Net Profit	249	229	260	205	255	277	275	253
EPS in Rs	14.68	13.49	15.36	12.08	15.05	16.36	16.23	14.95
Raw PDF	—	—	—	—	—	—	—	—

GLAXO profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,225	2,920	3,218	3,216	3,407	3,723	3,790	3,910
Expenses	2,566	2,323	2,462	2,417	2,507	2,553	2,490	2,567
Operating Profit	658	598	756	799	901	1,171	1,300	1,343
OPM %	20%	20%	23%	25%	26%	31%	34%	34%
Other Income	-247	8	1,402	104	-20	146	145	163
Interest	6	4	2	2	2	1	3	3
Depreciation	83	79	68	66	70	67	66	67
Profit before tax	322	524	2,087	835	809	1,248	1,376	1,436
Tax %	66%	32%	19%	27%	28%	26%	26%	—
Net Profit	110	358	1,691	608	585	919	1,012	1,060
EPS in Rs	6.50	21.11	99.79	35.88	34.51	54.25	59.73	62.59
Dividend Payout %	616%	142%	90%	89%	93%	100%	95%	—

GLAXO balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	169	169	169	169	169	169	169	169
Reserves	1,973	1,671	1,328	2,508	1,584	1,615	1,780	2,072
Borrowings	1	0	35	20	16	19	10	33
Other Liabilities	1,766	1,291	1,565	1,925	1,559	1,745	2,142	2,000
Total Liabilities	3,909	3,132	3,097	4,623	3,328	3,548	4,101	4,275
Fixed Assets	432	758	387	331	330	321	284	281
CWIP	1,003	120	13	30	20	14	14	33
Investments	25	24	24	390	543	838	1,143	1,416
Other Assets	2,450	2,229	2,672	3,871	2,435	2,375	2,660	2,545
Total Assets	3,909	3,132	3,097	4,623	3,328	3,548	4,101	4,275

GLAXO cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	411	491	595	820	488	579	1,280	881
Cash from Investing Activity	-154	-63	408	-420	805	15	-37	385
Cash from Financing Activity	-358	-428	-696	-524	-1,544	-562	-769	-737
Net Cash Flow	-102	0	307	-124	-251	32	474	530
Free Cash Flow	168	336	553	2,380	455	570	1,263	830
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	101%	103%	124%	124%	94%	92%	116%	92%

GLAXO shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%	75.00%
FIIs	4.50%	4.52%	4.89%	4.79%	4.63%	4.62%	4.79%	4.75%
DIIs	7.30%	7.79%	7.71%	7.75%	7.70%	7.68%	7.81%	8.47%
Government	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	13.21%	12.69%	12.41%	12.45%	12.67%	12.69%	12.42%	11.77%
No. of Shareholders	1,19,625	1,21,885	1,23,629	1,22,904	1,22,460	1,21,763	1,26,087	1,19,337

GLAXO key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	14	11	27	23	22	24	29	26
Inventory Days	131	135	153	144	128	146	124	119
Days Payable	109	99	131	156	122	174	188	152
Cash Conversion Cycle	37	47	49	11	27	-4	-36	-7
Working Capital Days	-72	-35	-38	-96	-59	-66	-102	-92
ROCE %	31%	33%	37%	36%	36%	51%	63%	61%

GLAXOUpdated 22 Oct 2026, 5:26

Glaxosmithkline Pharma Lt

GLAXOUpdated 22 Oct 2026, 5:26

Market Cap

₹41,748Cr.

Current Price

₹2,464

High / Low

₹3,121/2,088

Stock P/E

39.4

ROE43.3%

ROCE61.3%

Book Value₹132

Face Value₹10.0

Dividend Yield2.31%

About

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	738	0	597	54	16	179	27	131	7.71
Sep 2023	953	0	667	28	18	297	27	216	12.72
Dec 2023	805	0	587	-135	17	65	30	45	2.69
Mar 2024	911	1	656	32	18	269	28	193	11.4
Jun 2024	811	0	582	36	16	248	27	182	10.72
Sep 2024	1000	0	681	37	17	339	27	249	14.68
Dec 2024	946	0	656	35	19	306	25	229	13.49
Mar 2025	966	1	635	39	15	355	27	260	15.36
Jun 2025	805	0	554	44	16	279	27	205	12.08
Sep 2025	974	1	639	34	17	351	27	255	15.05
Dec 2025	1023	1	655	32	20	378	27	277	16.36
Mar 2026	989	1	642	36	13	369	26	275	16.23
Jun 2026	924	1	631	62	16	338	25	253	14.95

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2015 15m	3288	0	2660	147	25	749	37	472	27.84
Mar 2016	2826	0	2349	125	25	576	35	375	22.11
Mar 2017	2903	0	2482	118	27	511	34	337	19.88
Mar 2018	2872	0	2361	69	38	542	35	352	20.78
Mar 2019	3129	1	2522	106	49	664	36	425	25.11
Mar 2020	3225	6	2566	-247	83	322	66	110	6.5
Mar 2021	2920	4	2323	8	79	524	32	358	21.11
Mar 2022	3218	2	2462	1402	68	2087	19	1691	99.79
Mar 2023	3216	2	2417	104	66	835	27	608	35.88
Mar 2024	3407	2	2507	-20	70	809	28	585	34.51
Mar 2025	3723	1	2553	146	67	1248	26	919	54.25
Mar 2026	3790	3	2490	145	66	1376	26	1012	59.73
TTM	3910	3	2567	163	67	1436	—	1060	62.59

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	75%
FIIs	4.75%
DIIs	8.47%
Public	11.77%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	75%	2.93%	8.64%	0.01%	13.42%
Mar 2024	75%	3.48%	7.9%	0%	13.62%
Jun 2024	75%	4.02%	7.51%	0%	13.48%
Sep 2024	75%	4.36%	7.34%	0%	13.3%
Dec 2024	75%	4.5%	7.3%	0%	13.21%
Mar 2025	75%	4.52%	7.79%	0%	12.69%
Jun 2025	75%	4.89%	7.71%	0%	12.41%
Sep 2025	75%	4.79%	7.75%	0%	12.45%
Dec 2025	75%	4.63%	7.7%	0%	12.67%
Mar 2026	75%	4.62%	7.68%	0%	12.69%
Jun 2026	75%	4.79%	7.81%	0%	12.42%
Sep 2026	75%	4.75%	8.47%	0%	11.77%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2015	85	1767	3	1382	3236	123	115	48	2950	3236
Mar 2016	85	2120	2	864	3071	204	268	54	2545	3071
Mar 2017	85	1944	2	991	3021	258	605	48	2110	3021
Mar 2018	85	1995	1	1884	3965	325	923	48	2670	3965
Mar 2019	169	1973	1	1766	3909	432	1003	25	2450	3909
Mar 2020	169	1671	0	1291	3132	758	120	24	2229	3132
Mar 2021	169	1328	35	1565	3097	387	13	24	2672	3097
Mar 2022	169	2508	20	1925	4623	331	30	390	3871	4623
Mar 2023	169	1584	16	1559	3328	330	20	543	2435	3328
Mar 2024	169	1615	19	1745	3548	321	14	838	2375	3548
Mar 2025	169	1780	10	2142	4101	284	14	1143	2660	4101
Mar 2026	169	2072	33	2000	4275	281	33	1416	2545	4275

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2015	341	178	-497	22
Mar 2016	138	499	-638	-1
Mar 2017	232	303	-511	25
Mar 2018	475	-107	-307	61
Mar 2019	411	-154	-358	-102
Mar 2020	491	-63	-428	0
Mar 2021	595	408	-696	307
Mar 2022	820	-420	-524	-124
Mar 2023	488	805	-1544	-251
Mar 2024	579	15	-562	32
Mar 2025	1280	-37	-769	474
Mar 2026	881	385	-737	530

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	11	16	21	19	14	11	27	23	22	24	29	26
Inventory Days	89	155	111	147	131	135	153	144	128	146	124	119
Days Payable	74	96	72	148	109	99	131	156	122	174	188	152
Cash Conversion Cycle	26	75	61	18	37	47	49	11	27	-4	-36	-7
Working Capital Days	-49	25	6	-91	-72	-35	-38	-96	-59	-66	-102	-92
ROCE %	41%	28%	22%	26%	31%	33%	37%	36%	36%	51%	63%	61%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of GLAXOSMITHKLINE PHARMA LT (GLAXO)?

The reported market capitalisation for GLAXOSMITHKLINE PHARMA LT (GLAXO) is ₹41,748Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of GLAXO?

The current price shown for GLAXOSMITHKLINE PHARMA LT (GLAXO) on Fincrux is ₹2,464 with a 52-week high/low of ₹3,121/2,088.

What is the P/E ratio of GLAXOSMITHKLINE PHARMA LT (GLAXO)?

The stock P/E for GLAXOSMITHKLINE PHARMA LT (GLAXO) is 39.4 on Fincrux, with ROE at 43.3% and ROCE at 61.3%.

What were GLAXO latest quarterly results?

For Jun 2026, GLAXOSMITHKLINE PHARMA LT (GLAXO) reported sales ₹924 Cr and net profit ₹253 Cr (figures in ₹ crore unless noted).

What are GLAXO annual sales and net profit?

For TTM, GLAXOSMITHKLINE PHARMA LT (GLAXO) shows sales of ₹3,910 Cr and net profit of ₹1,060 Cr on the Fincrux profit & loss statement.

Who owns GLAXOSMITHKLINE PHARMA LT (GLAXO)?

Latest shareholding for GLAXOSMITHKLINE PHARMA LT (GLAXO) on Fincrux: Promoters 75.00% (Sep 2026), FIIs 4.75% (Sep 2026), DIIs 8.47% (Sep 2026), Government 0.00% (Sep 2026), Public 11.77% (Sep 2026).

Where can I find GLAXOSMITHKLINE PHARMA LT (GLAXO) financials?

GLAXOSMITHKLINE PHARMA LT (GLAXO) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show GLAXO balance sheet and cash flow?

Yes. The GLAXOSMITHKLINE PHARMA LT (GLAXO) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 22 October 2026 at 5:26